Artios Pharma's developing DNA damage response technology to treat cancer.
Investor deep dive
Arix Biosciences - venture capital firm flies under the market's radar
Artios in strong position to accelerate cancer programmes after Arix investment
Quick facts: Arix Bioscience PLC
Market Cap: £156.56 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE